Share This Article:

Histopathological Analysis about Autopsies from HIV/AIDS Patients—About Two Decades of Research Comparing Results before and after Antiretroviral Therapy Advent

Abstract Full-Text HTML Download Download as PDF (Size:128KB) PP. 207-215
DOI: 10.4236/wja.2013.33028    3,990 Downloads   5,435 Views  


Objectives: This study considers 489 autopsies of HIV/AIDS patients who died from acute respiratory failure and describes the demographic data, etiology, and histological pulmonary findings of HIV associated diseases, comparing results before and after introduction of antiretroviral therapy. Methods: The following data were obtained: age, sex, and major associated diseases (found at the autopsy). Pulmonary histopathology was categorized as: diffuse alveolar damage; pulmonary edema; alveolar hemorrhage; and acute interstitial pneumonia. Odds ratio of the HIV/AIDS-associated diseases developing a specific histopathological pattern was determined by logistic regression. Results: A total of 355 men were studied. The mean age was 37 years old. Bronchopneumonia presented in 43% and Pneumocystis jiroveci pneumonia in 38% of patients. Pulmonary histopathology showed diffuse alveolar damage in 31% and acute interstitial pneumonia in 23%. The multivariate analysis showed a significant and positive association between diffuse alveolar damage with disseminated tuberculosis, cirrhosis and sepsis; and acute interstitial pneumonia with Pneumocystis jiroveci pneumonia and cytomegalovirosis. After the introduction of antiretroviral therapy we observed an increase in the prevalence of bacterial bronchopneumonia, sepsis and cirrhosis; and a decrease in Pneumocystis jiroveci pneumonia and cytomegalovirosis. Conclusions: Coherent to literature, this study showed a decrease of respiratory failure mortality associated with some opportunistic infections after antiretroviral therapy introduction. But an increased prevalence of sepsis, bronchopneumonia and sepsis was observed too. The most prevalent pulmonary histopathological pattern was diffuse alveolar damage, which suggested a positive association with disseminated tuberculosis, sepsis and cirrhosis.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

A. Ruppert, A. Soeiro, M. Almeida, V. Capelozzi and C. Serrano Jr., "Histopathological Analysis about Autopsies from HIV/AIDS Patients—About Two Decades of Research Comparing Results before and after Antiretroviral Therapy Advent," World Journal of AIDS, Vol. 3 No. 3, 2013, pp. 207-215. doi: 10.4236/wja.2013.33028.


[1] J. M. Wallace, N. I. Hansen, L. Lavange, J. Glassroth, B. L. Browdy, M. J. Rosen, et al., “Respiratory Disease Trends in the Pulmonary Complications of HIV Infection Study Cohort. Pulmonary Complications of HIV Infection Study Group,” American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 1, 1997, pp. 72-80. doi:10.1164/ajrccm.155.1.9001292
[2] E. Casalino, G. Mendoza-Sassi, M. Wolff, J.-P. Bedos, C. Gaudebout, B. Regnier, et al., “Predictors of Short and Long-Term Survival in HIV-Infected Patients Admitted to the ICU,” Chest, Vol. 113, No. 2, 1998, pp. 421-429. doi:10.1378/chest.113.2.421
[3] E. Casalino, M. Wolff, P. Ravaud, C. Choquet, F. Bruneel and B. Regnier, “Impact of HAART Advent on Admission Patterns and Survival in HIV Infected Patients Admitted to an Intensive Care Unit,” AIDS, Vol. 18, No. 10, 2004, pp. 1429-1433. doi:10.1097/01.aids.0000131301.55204.a7
[4] M. Narasimhan, A. J. Posner, V. A. De Palo, P. H. Mayo and J. M. Rosen, “Intensive Care in Patients with HIV Infection in the Era of Highly Active Antiretroviral Therapy,” Chest, Vol. 125, No. 5, 2004, pp. 1800-1804. doi:10.1378/chest.125.5.1800
[5] R. M. Wachter, J. M. Luce, J. Turner, P. Volberding and P. C. Hopewell, “Intensive Care of Patients with the Acquired Immunodeficiency Syndrome: Outcome and Changing Patterns of Utilization,” American Review of Respiratory Disease, Vol. 134, No. 5, 1986, pp. 891-896.
[6] C. Alves, J. M. Nicolas, J. M. Miro, A. Torres, C. Agusti, J. Gonzales, et al., “Reappraisal of the Aetiology and Prognostic Factors of Severe Acute Respiratory Failure in HIV Patients,” European Respiratory Journal, Vol. 17, No. 1, 2001, pp. 87-93. doi:10.1183/09031936.01.17100870
[7] G. Nickas and R. M. Wachter, “Outcomes of Intensive Care for Patients with Human Immunodeficiency Virus Infection,” Archives of Internal Medicine, Vol. 160, No. 4, 2001, pp. 541-547. doi:10.1001/archinte.160.4.541
[8] B. Afessa and B. Green, “Clinical Course, Prognostic Factors, and Outcome Prediction for HIV Patients in the ICU. The PIP (Pulmonary Complications, ICU Support, and Prognostic Factors in Hospitalized Patients with HIV) Study,” Chest, Vol. 118, No. 1, 2000, pp. 138-145. doi:10.1378/chest.118.1.138
[9] B. Vincent, J.-F. Timsit, M. Auburtin, F. Schortgen, L. Bouadma, M. Wolff, et al., “Characteristics and Outcomes of HIV-Infected Patients in the ICU: Impact of the Highly Active Antiretroviral Treatment Era,” Intensive Care Medicine, Vol. 30, No. 5, 2004, pp. 859-866. doi:10.1007/s00134-004-2158-z
[10] D. N. Lanjewar and R. Dungal, “Pulmonary Pathology in Patients with AIDS: An Autopsy Study from Mumbai,” HIV Medicine, Vol. 2, No. 4, 2001, pp. 266-271. doi:10.1046/j.1468-1293.2001.00079.x
[11] B. Afessa, B. Green, J. Chiao and W. Frederick, “Pulmonary Complications of HIV Infection: Autopsy Findings,” Chest, Vol. 113, No. 5, 1998, pp. 1225-1229. doi:10.1378/chest.113.5.1225
[12] M. Canzian, A. M. Soeiro, M. F. L. Taga, C. Farhat, C. S. V. Barbas and V. L. Capelozzi, “Semiquantitative Assessment of Surgical Lung Biopsy: Predictive Value and Impact on Survival of Patients with Diffuse Pulmonary Infiltrate,” Clinics, Vol. 62, No. 1, 2007, pp. 23-30. doi:10.1590/S1807-59322007000100005
[13] B. Afessa and B. Green, “Bacterial Pneumonia in Hospitalized Patients with HIV Infection: The Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study,” Chest, Vol. 117, No. 4, 2000, pp. 1017-1022. doi:10.1378/chest.117.4.1017
[14] A. M. Soeiro, A. L. D. Hovnanian, E. R. Parra, M. Canzian and V. L. Capelozzi, “Post-Mortem Histological Pulmonary Analysis in Patients with HIV/AIDS,” Clinics, Vol. 63, No. 4, 2008, pp. 497-502. doi:10.1590/S1807-59322008000400014
[15] R. E. Hirschtick, J. Glassroth, M. C. Jordan, et al., “Bacterial Pneumonia in Persons Infected with the Human Immunodeficiency Virus. Pulmonary Complications of HIV Infection Study Group,” The New England Journal of Medicine, Vol. 333, No. 13, 1995, pp. 845-851. doi:10.1056/NEJM199509283331305
[16] B. Polsky, J. W. Gold, E. Whimbey, et al., “Bacterial Pneumonia in Patients with the Acquired Immunodeficiency Syndrome,” Annals of Internal Medicine, Vol. 104, No. 1, 1986, pp. 38-41. doi:10.7326/0003-4819-104-1-38
[17] D. J. Witt, D. E. Craven and W. R. McCabe, “Bacterial Infections in Adult Patients with the Acquired Immune Deficiency Syndrome (AIDS) and AIDS-Related Complex,” American Journal of Medicine, Vol. 82, No. 5, 1987, pp. 900-906. doi:10.1016/0002-9343(87)90150-1
[18] K. Ohtomo, S. Wang, A. Masunaga and I. Sugawara, “Secondary Infections of AIDS Autopsy Cases in Japan with Special Emphasis on Mycobacterium Avium-Intracellulare Complex Infection,” The Tohoku Journal of Experimental Medicine, Vol. 192, No. 2, 2000, pp. 99-109. doi:10.1620/tjem.192.99
[19] R. McKenzie, W. D. Travis, S. A. Dolan, S. Pittaluga, I. M. Feuerstein, J. Shelhamer, et al., “The Causes of Death in Patients with Human Immunodeficiency Virus Infection: A Clinical and Pathologic Study with Emphasis on the Role of Pulmonary Diseases,” Medicine (Baltimore), Vol. 70, No. 5, 1991, pp. 326-343. doi:10.1097/00005792-199109000-00004
[20] R. Nuesch, N. Geigy, E. Schaedler and M. Battegay, “Effect of Highly Active Antiretroviral Therapy on Hospitalization Characteristics of HIV-Infected Patients,” European Journal of Clinical Microbiology & Infectious Diseases, Vol. 21, No. 9, 2002, pp. 684-687. doi:10.1007/s10096-002-0792-3
[21] A. L. Rosenberg, M. G. Seneff, L. Atiyeh, R. Wagner, L. Bojanowski and J. E. Zimmerman, “The Importance of Bacterial Sepsis in Intensive Care Unit Patients with Acquired Immunodeficiency Syndrome: Implications for Future Care in the Age of Increasing Antiretroviral Resistance,” Critical Care Medicine, Vol. 29, No. 3, 2001, pp. 548-556. doi:10.1097/00003246-200103000-00013
[22] A. Morris, J. Creasman, J. Turner, J. M. Luce, R. M. Wachter and L. Huang, “Intensive Care of Human Immunodeficiency Virus-Infected Patients during the Era of Highly Active Antiretroviral Therapy,” American Journal of Respiratory and Critical Care Medicine, Vol. 166, No. 3, 2002, pp. 262-267. doi:10.1164/rccm.2111025
[23] H. Khouli, A. Afrasiabi, M. Shibli, R. Hajal, C. R. Barrett and P. Homel, “Outcome of Critically Ill Human Immunodeficiency Virus-Infected Patients in the Era of Highly Active Antiretroviral Therapy,” Journal of Intensive Care Medicine, Vol. 20, No. 6, 2005, pp. 327-333. doi:10.1177/0885066605281087
[24] K. Powell, J. L. Davis, A. M. Morris, A. Chi, M. R. Bensley and L. Huang, “Survival for Patients with HIV Admitted to the ICU Continues to Improve in the Current Era of Combination Antiretroviral Therapy,” Chest, Vol. 135, No. 1, 2009, pp. 11-17. doi:10.1378/chest.08-0980
[25] B. J. Glasgow, K. D. Steinsapir, K. Anders and L. J. Layfield, “Adrenal Pathology in the Acquired Immune Deficiency Syndrome,” American Journal of Clinical Pathology, Vol. 84, No. 5, 1985, pp. 594-597.
[26] U. Pulakhandam and H. P. Dincsoy, “Cytomegaloviraladrenalitis and Adrenal Insufficiency in AIDS,” American Journal of Clinical Pathology, Vol. 93, No. 5, 1990, pp. 651-656.
[27] K. Welch, W. Finkbeiner, C. E. Alpers, et al., “Autopsy Findings in the Acquired Immune Deficiency Syndrome,” JAMA, Vol. 252, No. 9, 1984, pp. 1152-1159. doi:10.1001/jama.1984.03350090028018
[28] N. Sonino, “The Use of Ketoconazole as an Inhibitor of Steroid Production,” The New England Journal of Medicine, Vol. 317, No. 13, 1987, pp. 812-818. doi:10.1056/NEJM198709243171307
[29] A. Torres, M. El-Ebiary, R. Marrades, et al., “Aetiology and Prognostic Factors of Patients with AIDS Presenting Life Threatening Acute Respiratory Failure,” European Respiratory Journal, Vol. 8, No. 11, 1995, pp. 1922-1928. doi:10.1183/09031936.95.08111922
[30] M. J. Rosen, K. Clayton, R. F. Schneider, et al., “Intensive Care of Patients with HIV Infection: Utilization, Critical Illnesses, and Outcomes. Pulmonary Complications of HIV Infection Study Group,” American Journal of Respiratory and Critical Care Medicine, Vol. 155, No. 1, 1997, pp. 67-71. doi:10.1164/ajrccm.155.1.9001291
[31] N. G. Mansharamani, R. Garland, D. Delaney and H. Koziel, “Management and Outcome Patterns for Adult Pneumocystis Carinii Pneumonia, 1985 to 1995: Comparison of HIV-Associated Cases to Other Immunocompromised States,” Chest, Vol. 118, No. 3, 2000, pp. 704-711. doi:10.1378/chest.118.3.704
[32] R. F. Miller, E. Allen, A. Copas, M. Singer and S. G. Edwards, “Improved Survival for HIV Infected Patients with Severe Pneumocystis Jirovecii Pneumonia Is Independent of Highly Active Antiretroviral Therapy,” Thorax, Vol. 61, No. 8, 2006, pp. 716-721. doi:10.1136/thx.2005.055905
[33] J. K. Gill, L. Greene, R. Miller, et al., “ICU Admission in Patients Infected with the Human Immunodeficiency Virus: A Multicentre Survey,” Anaesthesia, Vol. 54, No. 8, 1999, pp. 727-732. doi:10.1046/j.1365-2044.1999.00903.x
[34] R. Chakraborty, A. Pulver, L. S. Pulver, R. Musoke, T. Palakudy, A. D’Agostino, et al., “The Post-Mortem Pathology of HIV-1-Infected African Children,” Annals of Tropical Paediatrics, Vol. 22, No. 2, 2002, pp. 125-131. doi:10.1179/027249302125000841
[35] F. S. Rana, M. P. Hawken, C. Mwachari, S. M. Bhatt, F. Abdullah, L. W. Ng’ang’a, et al., “Autopsy Study of HIV-1-Positive and HIV-1-Negative Adult Medical Patients in Nairobi, Kenya,” Journal of Acquired Immune Deficiency Syndromes, Vol. 24, No. 1, 2000, pp. 23-29.
[36] N. A. Ansari, A. H. Kombe, T. A. Kenyon, N. M. Hone, J. W. Tappero, S. T. Nyirenda, et al., “Pathology and Causes of Death in a Group of 128 Predominantly HIV-Positive Patients in Botswana, 1997-1998,” The International Journal of Tuberculosis and Lung Disease, Vol. 6, No. 1, 2002, pp. 55-63.
[37] A. d’Arminio Monforte, L. Vago, A. Gori, S. Antinori, F. Franzetti, C. M. Antonacci, et al., “Clinical Diagnosis of Mycobacterial Diseases versus Autopsy Findings in 350 Patients with AIDS,” European Journal of Clinical Microbiology and Infectious Diseases, Vol. 15, No. 6, 1996, pp. 453-458. doi:10.1007/BF01691311
[38] M. N. Dhatz, K. Domoua, G. Coulibaly, F. Traore, J. B. Konan, A. Beaumel, et al., “Pulmonary Diseases and Retrovirus Infections. A Pathological Study in 70 Cases,” Revue de Pneumologie Clinique, Vol. 49, No. 5, 1993, pp. 211-215.
[39] P. M. Cury, C. F. Pulido, V. M. Furtado and F. M. Palma, “Autopsy Findings in AIDS Patients from a Reference Hospital in Brazil: Analysis of 92 Cases,” Pathology-Research and Practice, Vol. 199, No. 12, 2003, pp. 811-814. doi:10.1078/0344-0338-00500
[40] H. J. Tang, Y. C. Liu, M. Y. Yen, Y. S. Chen, S. R. Wann, H. H. Lin, et al., “Opportunistic Infections in Adults with Acquired Immunodeficiency Syndrome: A Comparison of Clinical and Autopsy Findings,” Journal of Microbiology, Immunology, and Infection, Vol. 39, No. 4, 2006, pp. 310-315.
[41] D. Eza, G. Cerrillo, D. A. Moore, C. Castro, E. Ticona, D. Morales et al., “Postmortem Findings and Opportunistic Infections in HIV-Positive Patients from a Public Hospital in Peru,” Pathology, Research and Practice, Vol. 202, No. 11, 2006, pp. 767-775.
[42] J. G. Netto, D. C. Collarile, A. F. Borges, M. L. Biancalana and H. N. Stefano, “Necroscopic Findings in Patients with Acquired Immunodeficiency Syndrome,” Revista Paulista de Medicina, Vol. 108, No. 5, 1990, pp. 205-212.
[43] E. C. Klatt and D. Shibata, “Cytomegalovirus Infection in the Acquired Immunodeficiency Syndrome. Clinical and Autopsy Findings,” Archives of Pathology & Laboratory Medicine, Vol. 112, No. 5, 1988, pp. 540-544.
[44] J. M. Wallace and J. Hannah, “Cytomegalovirus Pneumonitis in Patients with AIDS. Findings in an Autopsy Series,” Chest, Vol. 92, No. 2, 1987, pp. 198-203. doi:10.1378/chest.92.2.198
[45] P. Saleeb and K. N. Olivier, “Pulmonary Nontuberculous Mycobacterial Disease: New Insights into Risk Factors for Susceptibility, Epidemiology, and Approaches to Management in Immunocompetent and Immunocompromised Patients,” Current Infectious Disease Reports, Vol. 12, No. 3, 2010, pp. 198-203. doi:10.1007/s11908-010-0103-6
[46] N. F. Crum, R. H. Riffenburgh, S. Wegner, et al., “Comparisons of Causes of Death and Mortality Rates among HIV-Infected Persons: Analysis of the Pre-, Early, and Late HAART (Highly Active Antiretroviral Therapy) Eras,” Journal of Acquired Immune Deficiency Syndromes, Vol. 41, No. 2, 2006, pp. 194-200. doi:10.1097/01.qai.0000179459.31562.16
[47] R. S. Braithwaite, A. C. Justice, C. C. Chang, et al., “Estimating the Proportion of Patients Infected with HIV Who Will Die of Comorbid Diseases,” The American Journal of Medicine, Vol. 118, No. 8, 2005, pp. 890-898. doi:10.1016/j.amjmed.2004.12.034
[48] K. A. Mack and M. G. Ory, “AIDS and Older Americans at the End of the Twentieth Century,” Journal of Acquired Immune Deficiency Syndromes, Vol. 33, No. S2, 2003, pp. S68-S75. doi:10.1097/00126334-200306012-00003
[49] E. A. Operskalski, J. W. Mosley, M. P. Busch and D. O. Stram, “Influences of Age, Viral Load, and CD4+ Count on the Rate of Progression of HIV-1 Infection to AIDS,” Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, Vol. 15, No. 3, 1997, pp. 243-244. doi:10.1097/00042560-199707010-00009
[50] R. B. Effros, C. V. Fletcher, K. Gebo, et al., “Aging and Infectious Diseases: Workshop on HIV Infection and Aging: What Is Known and Future Research Directions,” Clinical Infectious Diseases, Vol. 47, No. 4, 2008, pp. 542-553. doi:10.1086/590150
[51] K. Crothers, A. A. Butt, C. L. Gibert, M. C. RodriguezBarradas, S. Crystal and A. C. Justice, “Increased COPD among HIV-Positive Compared to HIV-Negative Veterans,” Chest, Vol. 130, No. 5, 2006, pp. 1326-1333. doi:10.1378/chest.130.5.1326
[52] J. L. Goulet, S. L. Fultz, K. A. McGinnis and A. C. Justice, “Relative Prevalence of Comorbidities and Treatment Contraindications in HIV-Mono-Infected and HIV/HCV-Co-Infected Veterans,” AIDS, Vol. 19, Suppl. 3, 2005, pp. S99-S105. doi:10.1097/01.aids.0000192077.11067.e5
[53] H. K. Monga, M. C. Rodriguez-Barradas, K. Breaux, et al., “Hepatitis C Virus Infection-Related Morbidity and Mortality among Patients with Human Immunodeficiency Virus Infection,” Clinical Infectious Diseases, Vol. 33, No. 2, 2001, pp. 240-247. doi:10.1086/321819
[54] F. Bonnet, P. Morlat, G. Chene, et al., “Causes of Death among HIV-Infected Patients in the Era of Highly Active Antiretroviral Therapy, Bordeaux, France, 1998-1999,” HIV Medicine, Vol. 3, No. 3, 2002, pp. 195-199. doi:10.1046/j.1468-1293.2002.00117.x
[55] N. Friis-Moller, C. A. Sabin, R. Weber, et al., “Combination Antiretroviral Therapy and the Risk of Myocardial Infarction,” The New England Journal of Medicine, Vol. 349, No. 21, 2003, pp. 1993-2003. doi:10.1056/NEJMoa030218

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.